Form 4: Lynx1 Capital Acquires Pre-Funded Warrants in TScan Therapeutics, Potentially Limited by Ownership Blocker

Lynx1 Capital Management LP acquired pre-funded warrants for 5,000,000 shares of TScan Therapeutics, Inc., subject to an exercise limitation.

Summary

• Lynx1 Capital Management LP acquired pre-funded warrants to purchase 5,000,000 shares of TScan Therapeutics (TCRX) common stock on April 19, 2024.
• The exercise price of the pre-funded warrants is $0.0001.
• The warrants are subject to a 'Blocker' provision, which prevents the holder from exercising the warrants if doing so would result in the holder, together with related parties, beneficially owning more than 4.99% of TScan's outstanding common stock.
• Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable.
• Weston Nichols, as the sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, also filed a report disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports a transaction. The 'Blocker' provision introduces uncertainty, but the potential for future investment is a slight positive.

Positives

• The acquisition of pre-funded warrants represents a potential future investment in TScan Therapeutics by Lynx1 Capital.
• The nominal exercise price of $0.0001 per share provides a significant potential upside for Lynx1 Capital if the Blocker is removed and the warrants become exercisable.

Negatives

• The 'Blocker' provision significantly restricts the immediate value and exercisability of the warrants.
• The warrants are not presently exercisable due to the Blocker.

Risks

• The 'Blocker' provision may remain in place, preventing Lynx1 Capital from exercising the warrants and realizing their potential value.
• The value of the warrants is dependent on the future performance of TScan Therapeutics' stock price.

Future Outlook

The future value of the warrants depends on TScan's stock performance and whether the 'Blocker' provision is removed, allowing Lynx1 Capital to exercise the warrants.

Industry Context

Form 4 filings are standard disclosures for significant transactions by company insiders and large shareholders, providing transparency to the market.

Comparison to Industry Standards

• Pre-funded warrants are a relatively common financing tool, particularly for smaller companies.
• The 'Blocker' provision is a mechanism used to prevent an investor from triggering certain regulatory thresholds or takeover defenses.

Stakeholder Impact

• The acquisition of warrants could signal confidence in TScan's future prospects, potentially benefiting shareholders.
• The 'Blocker' provision limits the immediate impact of the transaction.

Key Dates